Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Gold nanoparticles (AuNPs) have recently attracted attention as clinical agents for enhancing the effect of radiotherapy in various cancers. Although radiotherapy is a standard treatment for cancers, invasive recurrence and metastasis are significant clinical problems. Several studies have suggested that radiation promotes the invasion of cancer cells by activating molecular mechanisms involving integrin and fibronectin (FN). In this study, polyethylene-glycolylated AuNPs (P-AuNPs) were conjugated with Arg-Gly-Asp (RGD) peptides (RGD/P-AuNPs) to target cancer cells expressing RGD-binding integrins such as α5- and αv-integrins. RGD/P-AuNPs were internalized more efficiently and colocalized with integrins in the late endosomes and lysosomes of MDA-MB-231 cells. A combination of RGD/P-AuNPs and radiation reduced cancer cell viability and increased DNA damage compared to radiation alone in MDA-MB-231 cells. Moreover, the invasive activity of breast cancer cell lines after radiation treatment was significantly inhibited in the presence of RGD/P-AuNPs. Microarray analyses revealed that the expression of FN in irradiated cells was suppressed by combined use of RGD/P-AuNPs. Reduction of FN and downstream signaling may be involved in suppressing radiation-induced invasive activity by RGD/P-AuNPs. Our study suggests that RGD/P-AuNPs can target integrin-overexpressing cancer cells to improve radiation therapy by suppressing invasive activity in addition to sensitization. Thus, these findings provide a possible clinical strategy for using AuNPs to treat invasive breast cancer following radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974 · cited 1×
“14,15 Although lower doses are utilized for clinical treatment, 19.3% of breast cancer patients develop invasive recurrent disease following radiotherapy.”
BackgroundInfluentialRab proteins as membrane organizers
Zerial, M., & McBride, H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052055 · Cited by 3,381
The Rab5 effector EEA1 is a core component of endosome docking
Christoforidis, S., McBride, H. M., Burgoyne, R. D., & Zerial, M. (1999) · Nature · doi:10.1038/17618 · Cited by 854
Nam, J.-M., Onodera, Y., Bissell, M. J., & Park, C. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2319 · Cited by 196
Self-citation
Cited by
X-ray-activated nanosystems for theranostic applications
Chen, X., Song, J., Chen, X., & Yang, H. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00921j · Cited by 401
Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy
Chen, Y., Yang, J., Fu, S., & Wu, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272902 · Cited by 319
Active targeting of gold nanoparticles as cancer therapeutics
Goddard, Z. R., Marín, M. J., Russell, D. A., & Searcey, M. (2020) · Chemical Society Reviews · doi:10.1039/d0cs01121e · Cited by 282
Bilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52
Musielak, M., Boś-Liedke, A., Piwocka, O., Kowalska, K., Markiewicz, R., Szymkowiak, B., Bakun, P., & Suchorska, W. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030862 · Cited by 18
Metadata
- Authors
- Wu, P.-H., Onodera, Y., Ichikawa, Y., Rankin, E., Giaccia, A., Watanabe, Y., Qian, W., Hashimoto, T., Shirato, H., & Nam, J.-M.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-07
- Volume
- Volume 12
- Pages
- 5069-5085
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2735495803
- Cited by
- 132
- References
- 5
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.